<?xml version='1.0' encoding='utf-8'?>
<document id="22799027"><sentence text="[Evaluation of P-glycoprotein mediated in vitro loperamide biliary excretion with sandwich-cultured rat hepatocytes model]." /><sentence text="An in vitro P-glycoprotein mediated drug biliary excretion model (B-Clear model) was developed and validated using sandwich-cultured rat hepatocytes (SCRH) and a model substrate rhodamine 123 (Rh123)" /><sentence text=" SCRH formed functional bile canalicular networks after 5 days of culture" /><sentence text=" Rh123 (10 micromol x L(-1)) was then incubated with the SCRH in standard Ca+ Hanks buffer or Ca(2+)-free buffer" /><sentence text=" The cumulative cell uptake and canalicular efflux of Rh123 under Ca2+ and Ca(2+)-free conditions were measured with a LC-MS/MS method"><entity charOffset="66-70" id="DDI-PubMed.22799027.s5.e0" text="Ca2+" /></sentence><sentence text=" The biliary excretion index (BEI) and instinct biliary clearance (CL(bile, int)) were calculated" /><sentence text=" To assess the effect of known P-gp inhibitors on the efflux of Rh123, cyclosporine A (CyA), tariquidar (TQD) or quinidine (QND) (10, 50 and 100 micromol x L(-1)) was pre-incubated separately with SCRH for 30 min, then co-incubated with Rh123"><entity charOffset="71-85" id="DDI-PubMed.22799027.s7.e0" text="cyclosporine A" /><entity charOffset="113-122" id="DDI-PubMed.22799027.s7.e1" text="quinidine" /><pair ddi="false" e1="DDI-PubMed.22799027.s7.e0" e2="DDI-PubMed.22799027.s7.e0" /><pair ddi="false" e1="DDI-PubMed.22799027.s7.e0" e2="DDI-PubMed.22799027.s7.e1" /></sentence><sentence text=" The BEI and CL(bile, int) of Rh123 obtained from the SCRH model were (17" /><sentence text="8 +/- 1" /><sentence text="3) % and (10" /><sentence text="7 +/- 0" /><sentence text="9) mL x min(-1) x kg(-1), respectively" /><sentence text=" All the three P-gp inhibitors showed a dose-dependent inhibition on the bile clearance of Rh123, indicating that the B-Clear model with SCRH was functional properly" /><sentence text=" The biliary excretion of loperamide (LPAD) and the role of P-gp were further investigated with this validated model"><entity charOffset="26-36" id="DDI-PubMed.22799027.s14.e0" text="loperamide" /><entity charOffset="38-42" id="DDI-PubMed.22799027.s14.e1" text="LPAD" /><pair ddi="false" e1="DDI-PubMed.22799027.s14.e0" e2="DDI-PubMed.22799027.s14.e0" /><pair ddi="false" e1="DDI-PubMed.22799027.s14.e0" e2="DDI-PubMed.22799027.s14.e1" /></sentence><sentence text=" The BEI and CL(bile, int) for LPAD (20 micromol x L(-1)) were obtained after it was incubated with SCRH for 30 min, and found to be (12"><entity charOffset="31-34" id="DDI-PubMed.22799027.s15.e0" text="LPAD" /></sentence><sentence text="9 +/- 1" /><sentence text="2)% and (6" /><sentence text="1 +/- 0" /><sentence text="3) mL x min(-1) x kg(-1) respectively" /><sentence text=" The dose-dependent inhibition on LPAD biliary excretion by CyA, TQD or QND confirmed the major role of P-gp in LPAD canalicular efflux"><entity charOffset="34-37" id="DDI-PubMed.22799027.s20.e0" text="LPAD" /><entity charOffset="112-115" id="DDI-PubMed.22799027.s20.e1" text="LPAD" /><pair ddi="false" e1="DDI-PubMed.22799027.s20.e0" e2="DDI-PubMed.22799027.s20.e0" /><pair ddi="false" e1="DDI-PubMed.22799027.s20.e0" e2="DDI-PubMed.22799027.s20.e1" /></sentence><sentence text=" The results suggested that the B-Clear model with SCRH would be a useful tool for evaluation of P-gp mediated efflux and drug-drug interaction" /><sentence text="" /></document>